Home > Publications Database > Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. > print

001     136528
005     20240424120353.0
024 7 _ |a 10.1186/1742-2094-9-44
|2 doi
024 7 _ |a pmid:22373413
|2 pmid
024 7 _ |a pmc:PMC3359160
|2 pmc
037 _ _ |a DZNE-2020-02850
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Röhnert, Peter
|b 0
245 _ _ |a Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia.
260 _ _ |a London
|c 2012
|b BioMed Central
264 _ 1 |3 online
|2 Crossref
|b Springer Science and Business Media LLC
|c 2012-02-28
264 _ 1 |3 print
|2 Crossref
|b Springer Science and Business Media LLC
|c 2012-12-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1713881149_10934
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cerebral inflammation is a hallmark of neuronal degeneration. Dipeptidyl peptidase IV, aminopeptidase N as well as the dipeptidyl peptidases II, 8 and 9 and cytosolic alanyl-aminopeptidase are involved in the regulation of autoimmunity and inflammation. We studied the expression, localisation and activity patterns of these proteases after endothelin-induced occlusion of the middle cerebral artery in rats, a model of transient and unilateral cerebral ischemia.Male Sprague-Dawley rats were used. RT-PCR, immunohistochemistry and protease activity assays were performed at different time points, lasting from 2 h to 7 days after cerebral ischemia. The effect of protease inhibitors on ischemia-dependent infarct volumes was quantified 7 days post middle cerebral artery occlusion. Statistical analysis was conducted using the t-test.Qualitative RT-PCR revealed these proteases in ipsilateral and contralateral cortices. Dipeptidyl peptidase II and aminopeptidase N were up-regulated ipsilaterally from 6 h to 7 days post ischemia, whereas dipeptidyl peptidase 9 and cytosolic alanyl-aminopeptidase were transiently down-regulated at day 3. Dipeptidyl peptidase 8 and aminopeptidase N immunoreactivities were detected in cortical neurons of the contralateral hemisphere. At the same time point, dipeptidyl peptidase IV, 8 and aminopeptidase N were identified in activated microglia and macrophages in the ipsilateral cortex. Seven days post artery occlusion, dipeptidyl peptidase IV immunoreactivity was found in the perikarya of surviving cortical neurons of the ipsilateral hemisphere, whereas their nuclei were dipeptidyl peptidase 8- and amino peptidase N-positive. At the same time point, dipeptidyl peptidase IV, 8 and aminopeptidase N were targeted in astroglial cells. Total dipeptidyl peptidase IV, 8 and 9 activities remained constant in both hemispheres until day 3 post experimental ischemia, but were increased (+165%) in the ipsilateral cortex at day 7. In parallel, aminopeptidase N and cytosolic alanyl-aminopeptidase activities remained unchanged.Distinct expression, localization and activity patterns of proline- and alanine-specific proteases indicate their involvement in ischemia-triggered inflammation and neurodegeneration. Consistently, IPC1755, a non-selective protease inhibitor, revealed a significant reduction of cortical lesions after transient cerebral ischemia and may suggest dipeptidyl peptidase IV, aminopeptidase N and proteases with similar substrate specificity as potentially therapy-relevant targets.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
542 _ _ |i 2012-02-28
|2 Crossref
|u http://www.creativecommons.org/licenses/by/2.0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Enzyme Inhibitors
|2 NLM Chemicals
650 _ 7 |a Glial Fibrillary Acidic Protein
|2 NLM Chemicals
650 _ 7 |a Glycosphingolipids
|2 NLM Chemicals
650 _ 7 |a RNA, Messenger
|2 NLM Chemicals
650 _ 7 |a inositolphosphorylceramide
|2 NLM Chemicals
650 _ 7 |a CD13 Antigens
|0 EC 3.4.11.2
|2 NLM Chemicals
650 _ 7 |a Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
|0 EC 3.4.14.-
|2 NLM Chemicals
650 _ 7 |a Dpp8 protein, rat
|0 EC 3.4.14.-
|2 NLM Chemicals
650 _ 7 |a Dipeptidyl Peptidase 4
|0 EC 3.4.14.5
|2 NLM Chemicals
650 _ 7 |a Phosphopyruvate Hydratase
|0 EC 4.2.1.11
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Brain Ischemia: complications
|2 MeSH
650 _ 2 |a Brain Ischemia: drug therapy
|2 MeSH
650 _ 2 |a Brain Ischemia: enzymology
|2 MeSH
650 _ 2 |a CD13 Antigens: genetics
|2 MeSH
650 _ 2 |a CD13 Antigens: metabolism
|2 MeSH
650 _ 2 |a Cerebral Infarction: enzymology
|2 MeSH
650 _ 2 |a Cerebral Infarction: etiology
|2 MeSH
650 _ 2 |a Dipeptidyl Peptidase 4: genetics
|2 MeSH
650 _ 2 |a Dipeptidyl Peptidase 4: metabolism
|2 MeSH
650 _ 2 |a Dipeptidyl-Peptidases and Tripeptidyl-Peptidases: genetics
|2 MeSH
650 _ 2 |a Dipeptidyl-Peptidases and Tripeptidyl-Peptidases: metabolism
|2 MeSH
650 _ 2 |a Disease Models, Animal
|2 MeSH
650 _ 2 |a Enzyme Inhibitors: therapeutic use
|2 MeSH
650 _ 2 |a Functional Laterality
|2 MeSH
650 _ 2 |a Gene Expression Regulation, Enzymologic: physiology
|2 MeSH
650 _ 2 |a Glial Fibrillary Acidic Protein: metabolism
|2 MeSH
650 _ 2 |a Glycosphingolipids: therapeutic use
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Phosphopyruvate Hydratase: metabolism
|2 MeSH
650 _ 2 |a RNA, Messenger: metabolism
|2 MeSH
650 _ 2 |a Rats
|2 MeSH
650 _ 2 |a Rats, Sprague-Dawley
|2 MeSH
650 _ 2 |a Time Factors
|2 MeSH
700 1 _ |a Schmidt, Werner
|0 P:(DE-2719)9000421
|b 1
|u dzne
700 1 _ |a Emmerlich, Patrick
|b 2
700 1 _ |a Goihl, Alexander
|b 3
700 1 _ |a Wrenger, Sabine
|b 4
700 1 _ |a Bank, Ute
|b 5
700 1 _ |a Nordhoff, Karsten
|b 6
700 1 _ |a Täger, Michael
|b 7
700 1 _ |a Ansorge, Siegfried
|b 8
700 1 _ |a Reinhold, Dirk
|b 9
700 1 _ |a Striggow, Frank
|0 P:(DE-2719)9000420
|b 10
|e Last author
|u dzne
773 1 8 |a 10.1186/1742-2094-9-44
|b : Springer Science and Business Media LLC, 2012-02-28
|n 1
|p 557
|3 journal-article
|2 Crossref
|t Journal of Neuroinflammation
|v 9
|y 2012
|x 1742-2094
773 _ _ |a 10.1186/1742-2094-9-44
|g Vol. 9, no. 1, p. 557
|0 PERI:(DE-600)2156455-3
|n 1
|q 9:1<557
|p 557
|t Journal of neuroinflammation
|v 9
|y 2012
|x 1742-2094
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/136528/files/DZNE-2020-02850.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/136528/files/DZNE-2020-02850.pdf?subformat=pdfa
856 7 _ |2 Pubmed Central
|u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359160
909 C O |o oai:pub.dzne.de:136528
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000421
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9000420
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 0
914 1 _ |y 2012
915 _ _ |a Creative Commons Attribution CC BY 2.0
|0 LIC:(DE-HGF)CCBY2
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROINFLAMM : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J NEUROINFLAMM : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
920 1 _ |0 I:(DE-2719)5000045
|k AG Striggow
|l Neurodegeneration and Intervention Strategies
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000045
980 1 _ |a FullTexts
999 C 5 |9 -- missing cx lookup --
|a 10.1097/00019052-200102000-00014
|2 Crossref
|o 10.1097/00019052-200102000-00014
999 C 5 |9 -- missing cx lookup --
|a 10.1002/glia.20205
|2 Crossref
|o 10.1002/glia.20205
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.surneu.2005.12.028
|2 Crossref
|o 10.1016/j.surneu.2005.12.028
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.pbb.2007.04.015
|2 Crossref
|o 10.1016/j.pbb.2007.04.015
999 C 5 |9 -- missing cx lookup --
|a 10.1189/jlb.1109766
|2 Crossref
|o 10.1189/jlb.1109766
999 C 5 |9 -- missing cx lookup --
|a 10.1097/00004647-199811000-00001
|2 Crossref
|o 10.1097/00004647-199811000-00001
999 C 5 |9 -- missing cx lookup --
|a 10.1097/00004647-199908000-00001
|2 Crossref
|o 10.1097/00004647-199908000-00001
999 C 5 |9 -- missing cx lookup --
|a 10.1016/0167-5699(94)90316-6
|2 Crossref
|o 10.1016/0167-5699(94)90316-6
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S0167-5699(99)01486-3
|2 Crossref
|o 10.1016/S0167-5699(99)01486-3
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S0167-4838(01)00278-3
|2 Crossref
|o 10.1016/S0167-4838(01)00278-3
999 C 5 |9 -- missing cx lookup --
|a 10.1042/CS20040302
|2 Crossref
|o 10.1042/CS20040302
999 C 5 |9 -- missing cx lookup --
|a 10.2174/0929867053507298
|2 Crossref
|o 10.2174/0929867053507298
999 C 5 |9 -- missing cx lookup --
|a 10.1189/jlb.0906546
|2 Crossref
|o 10.1189/jlb.0906546
999 C 5 |y 1999
|2 Crossref
|o T Kähne 1999
999 C 5 |9 -- missing cx lookup --
|a 10.1080/713609354
|2 Crossref
|o 10.1080/713609354
999 C 5 |9 -- missing cx lookup --
|a 10.1016/B978-012369442-3/50084-2
|2 Crossref
|o 10.1016/B978-012369442-3/50084-2
999 C 5 |9 -- missing cx lookup --
|a 10.1515/bc.2011.008
|2 Crossref
|o 10.1515/bc.2011.008
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S0167-5699(98)01398-X
|2 Crossref
|o 10.1016/S0167-5699(98)01398-X
999 C 5 |y 1999
|2 Crossref
|o U Lendeckel 1999
999 C 5 |9 -- missing cx lookup --
|a 10.1515/BC.2003.073
|2 Crossref
|o 10.1515/BC.2003.073
999 C 5 |9 -- missing cx lookup --
|a 10.1016/0736-5748(87)90034-7
|2 Crossref
|o 10.1016/0736-5748(87)90034-7
999 C 5 |9 -- missing cx lookup --
|a 10.1006/geno.1994.1094
|2 Crossref
|o 10.1006/geno.1994.1094
999 C 5 |9 -- missing cx lookup --
|a 10.1016/0169-328X(94)90164-3
|2 Crossref
|o 10.1016/0169-328X(94)90164-3
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.neulet.2005.03.061
|2 Crossref
|o 10.1016/j.neulet.2005.03.061
999 C 5 |9 -- missing cx lookup --
|a 10.2741/2846
|2 Crossref
|o 10.2741/2846
999 C 5 |9 -- missing cx lookup --
|a 10.1016/0006-8993(84)90036-2
|2 Crossref
|o 10.1016/0006-8993(84)90036-2
999 C 5 |9 -- missing cx lookup --
|a 10.1007/BF00489918
|2 Crossref
|o 10.1007/BF00489918
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S0968-0896(00)00231-5
|2 Crossref
|o 10.1016/S0968-0896(00)00231-5
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.biocel.2005.12.013
|2 Crossref
|o 10.1016/j.biocel.2005.12.013
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S0166-2236(99)01401-0
|2 Crossref
|o 10.1016/S0166-2236(99)01401-0
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S0960-894X(02)00603-0
|2 Crossref
|o 10.1016/S0960-894X(02)00603-0
999 C 5 |9 -- missing cx lookup --
|a 10.2337/diabetes.54.10.2988
|2 Crossref
|o 10.2337/diabetes.54.10.2988
999 C 5 |9 -- missing cx lookup --
|a 10.1016/0165-0270(95)00003-D
|2 Crossref
|o 10.1016/0165-0270(95)00003-D
999 C 5 |y 2005
|2 Crossref
|t The rat brain in stereotoxic coordinates
|o G Paxinos The rat brain in stereotoxic coordinates 2005

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21